Enhancing the clinical potential of relaxin
Grant number: 1023078 | Funding period: 2012 - 2014
The hormone relaxin mediates cardiovascular and kidney changes during pregnancy. These important functions have led to its current use in clinical trials for the treatment of acute heart failure, a condition affecting millions of patients worldwide. However, there is an urgent need for a longer lasting form of relaxin for prolonged treatment of patients. Our studies will focus on understanding the blood breakdown of the peptide to lead to the design of longer lasting relaxin analogues.
Related publications (12)
The C-terminus of the B-chain of human insulin-like peptide 5 is critical for cognate RXFP4 receptor activity
Nitin A Patil, Ross AD Bathgate, Martina Kocan, Sheng Yu Ang, Julien Tailhades, Frances Separovic, Roger Summers, Johannes Grosse, Richard A Hughes, John D Wade, Mohammed Akhter Hossain